Hillsdale Investment Management Inc. Pacira Bio Sciences, Inc. Transaction History
Hillsdale Investment Management Inc.
- $1.21 Billion
- Q3 2024
A detailed history of Hillsdale Investment Management Inc. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Hillsdale Investment Management Inc. holds 229,200 shares of PCRX stock, worth $4.46 Million. This represents 0.29% of its overall portfolio holdings.
Number of Shares
229,200
Previous 95,100
141.01%
Holding current value
$4.46 Million
Previous $2.72 Million
26.88%
% of portfolio
0.29%
Previous 0.24%
Shares
8 transactions
Others Institutions Holding PCRX
# of Institutions
263Shares Held
50.4MCall Options Held
429KPut Options Held
391K-
Black Rock Inc. New York, NY8.01MShares$156 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.3MShares$103 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA4.96MShares$96.6 Million0.18% of portfolio
-
State Street Corp Boston, MA2.01MShares$39.2 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.98MShares$38.5 Million0.05% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $892M
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...